Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study

Published:2023-10 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Nukaya Takuhisa,Takahara Kiyoshi,Yoshizawa Atsuhiko,Saruta Masanobu,Yano Yusuke,Ohno Takaya,Uchimoto Taizo,Fukuokaya Wataru,Adachi Takahiro,Yamazaki Shogo,Tokushige Satoshi,Nishimura Kazuki,Tsujino Takuya,Nakamori Keita,Yamamoto Shutaro,Iwatani Kosuke,Urabe Fumihiko,Mori Keiichiro^ORCID,Yanagisawa Takafumi^ORCID,Tsuduki Shunsuke,Hirasawa Yosuke,Hashimoto Takeshi,Komura Kazumasa,Inamoto Teruo,Miki Jun,Kimura Takahiro^ORCID,Ohno Yoshio,Azuma Haruhito,Shiroki Ryoichi

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference44 articles.

1. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial;Albiges;ESMO Open,2020

2. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

3. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

4. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

5. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

2. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma;Immunotherapy;2024-01-24